Ongoing study
Official Study Title
CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS
Brief Description
The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with community-acquired pneumonia (CAP), sepsis, and sepsis-induced immunoparalysis (SII). The primary objective is to evaluate the effect of clarithromycin on the incidence of new infection, including worsening or recurrence of the initial CAP episode, new infections at other sites, and secondary sepsis during the 28-day follow-up period. Secondary objectives are to investigate the impact of clarithromycin on mortality, sepsis response, type of secondary infection, time to antimicrobial escalation, hospital readmission, quality of life, cost-effectiveness, and biomarkers of sepsis-induced immunoparalysis.
Details
Status: Recruiting
Study Type: Interventional (Clinical Trial)
Study phase: III
Study sites: 19 sites in Greece
Target of enrolment: 252 participants
ClinicalTrials.gov Identifier: NCT07834346
CTIS number: 2025-525058-20-00
Study Start: September 2026
Condition/Disease studied: community-acquired pneumonia (CAP), sepsis, and sepsis-induced immunoparalysis (SII)
Keywords: clarithromycin
Connect to the CLASSIFY trial portal